FDA Signals New Testosterone Pathway - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

  • By

  • Kathryn Wighton

  • April 16, 2026

  • 2 min

Share

  • 1

    The FDA is encouraging sponsors of testosterone replacement therapy to pursue a new indication for low libido in men with idiopathic hypogonadism.

  • 2

    Currently, TRT products are approved only for men with hypogonadism due to established structural or genetic causes.

  • 3

    The FDA's review indicated that TRT may be safe and effective for men with decreased libido linked to idiopathic hypogonadism.

  • 4

    Sponsors are advised to contact the FDA by April 30 to discuss submission requirements for supplemental applications.

  • 5

    Any new indication approval will require substantial evidence of effectiveness and a favorable risk-benefit assessment.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Upfront Cost Guidance Limited in US Guidelines

Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.

Telemedicine-Based Diabetes Management for Incarcerated Individuals

Do Revisions in Rotator Cuff Repair Decline With GLP-1 Use?

Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.